361 related articles for article (PubMed ID: 37559935)
1. Advances in targeted therapy and immunotherapy for melanoma (Review).
Qin Z; Zheng M
Exp Ther Med; 2023 Sep; 26(3):416. PubMed ID: 37559935
[TBL] [Abstract][Full Text] [Related]
2. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
3. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
Front Immunol; 2019; 10():990. PubMed ID: 31134073
[TBL] [Abstract][Full Text] [Related]
4. A review of novel therapies for melanoma.
Karimkhani C; Gonzalez R; Dellavalle RP
Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
Koppolu V; Rekha Vasigala VK
J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
[TBL] [Abstract][Full Text] [Related]
8. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
9. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang T; Eldabaje R; Yang L
Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Advanced Melanoma: Past, Present and Future.
Fujimura T; Kambayashi Y; Ohuchi K; Muto Y; Aiba S
Life (Basel); 2020 Sep; 10(9):. PubMed ID: 32948031
[TBL] [Abstract][Full Text] [Related]
11. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy.
Falcone I; Conciatori F; Bazzichetto C; Ferretti G; Cognetti F; Ciuffreda L; Milella M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33036192
[TBL] [Abstract][Full Text] [Related]
13. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
14. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
15. Treatment algorithm of metastatic mucosal melanoma.
Wang X; Si L; Guo J
Chin Clin Oncol; 2014 Sep; 3(3):38. PubMed ID: 25841464
[TBL] [Abstract][Full Text] [Related]
16. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
17. [Understanding current therapies in metastatic melanoma].
Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trials in Melanoma: Margins, Lymph Nodes, Targeted and Immunotherapy.
Sharon CE; Beasley GM; Karakousis GC
Surg Oncol Clin N Am; 2023 Jan; 32(1):47-63. PubMed ID: 36410921
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
Zhou AY; Johnson DB
Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-based combinations: an update.
Fucà G; de Braud F; Di Nicola M
Curr Opin Oncol; 2018 Sep; 30(5):345-351. PubMed ID: 29994900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]